Yong S. Chang

Yong joined Ring from KorroBio where he was responsible for all aspects of Development, including target biology, translational sciences, CMC, preclinical and clinical development. Previously, he was at Intellia Therapeutics where he led the first systemically delivered CRISPR/Cas gene editing candidate to the clinic. Yong brings over 20 years of preclinical and drug development experience from both large pharma and biotech at Aileron Therapeuics, MedImmune/AstraZeneca, Bayer and Roche. Yong was a post-doctoral research Fellow at Harvard Medical School/MGH. He received his PhD in physiology and BS in biology from The Pennsylvania State University.